CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2)
Status:
Active, not recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label study to evaluate the safety profile of CORVax +/- pIL-12,
(electroporated SARS-CoV-2 spike (S) protein plasmid DNA vaccine with or without the
combination of electroporated IL-12p70 plasmid.